Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ADIPemCis) (TRAP Study)

NCT02029690 is registered in ClinicalTrials.gov with Polaris Group as lead sponsor.

NCT NCT02029690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02029690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ADIPemCis) (TRAP Study)
Lead sponsor
Polaris Group
Phase
Phase 1
Overall status
Terminated
Start date
April 23, 2014
Completion date
June 30, 2020
Enrollment
85 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

glioma, hepatocellular carcinoma, non-squamous non-small cell lung carcinoma, peritoneal mesothelioma malignant advanced, pleural mesothelioma malignant advanced, sarcomatoid carcinoma, uveal melanoma